JP2008525416A5 - - Google Patents

Download PDF

Info

Publication number
JP2008525416A5
JP2008525416A5 JP2007547681A JP2007547681A JP2008525416A5 JP 2008525416 A5 JP2008525416 A5 JP 2008525416A5 JP 2007547681 A JP2007547681 A JP 2007547681A JP 2007547681 A JP2007547681 A JP 2007547681A JP 2008525416 A5 JP2008525416 A5 JP 2008525416A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
pharmaceutically acceptable
hydrogen
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007547681A
Other languages
English (en)
Japanese (ja)
Other versions
JP4980928B2 (ja
JP2008525416A (ja
Filing date
Publication date
Priority claimed from GB0428212A external-priority patent/GB0428212D0/en
Priority claimed from GB0513255A external-priority patent/GB0513255D0/en
Application filed filed Critical
Priority claimed from PCT/GB2005/050264 external-priority patent/WO2006067531A1/en
Publication of JP2008525416A publication Critical patent/JP2008525416A/ja
Publication of JP2008525416A5 publication Critical patent/JP2008525416A5/ja
Application granted granted Critical
Publication of JP4980928B2 publication Critical patent/JP4980928B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007547681A 2004-12-24 2005-12-23 Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用 Expired - Fee Related JP4980928B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0428212A GB0428212D0 (en) 2004-12-24 2004-12-24 Compounds
GB0428212.5 2004-12-24
GB0513255.0 2005-06-30
GB0513255A GB0513255D0 (en) 2005-06-30 2005-06-30 Compounds
PCT/GB2005/050264 WO2006067531A1 (en) 2004-12-24 2005-12-23 G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes

Publications (3)

Publication Number Publication Date
JP2008525416A JP2008525416A (ja) 2008-07-17
JP2008525416A5 true JP2008525416A5 (enExample) 2008-12-11
JP4980928B2 JP4980928B2 (ja) 2012-07-18

Family

ID=36601424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547681A Expired - Fee Related JP4980928B2 (ja) 2004-12-24 2005-12-23 Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用

Country Status (10)

Country Link
US (1) US20080312281A1 (enExample)
EP (1) EP1838311A1 (enExample)
JP (1) JP4980928B2 (enExample)
KR (1) KR20070091038A (enExample)
AU (1) AU2005317769A1 (enExample)
BR (1) BRPI0516407A (enExample)
CA (1) CA2591922A1 (enExample)
MX (1) MX2007007553A (enExample)
NZ (1) NZ556017A (enExample)
WO (1) WO2006067531A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7759491B2 (en) * 2005-04-28 2010-07-20 Kyowa Hakko Kirin Co., Ltd. Method for producing indazol-3-ylmethyl phosphonium salt
US20090203676A1 (en) * 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
EP2308840A1 (en) * 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
BRPI0710597A2 (pt) 2006-04-11 2012-06-19 Arena Pharm Inc método de uso do receptor gpr119 para identificar compostos úteis para aumento da massa óssea em um indivìduo
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
EP2112880A4 (en) * 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
EP2114936A1 (en) 2007-01-04 2009-11-11 Prosidion Limited Piperidine gpcr agonists
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
ES2373181T3 (es) * 2007-01-04 2012-02-01 Prosidion Ltd Agonistas de gpcr de piperidina.
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
AR064735A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2200609A1 (en) * 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US8343990B2 (en) 2008-04-14 2013-01-01 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
WO2013062838A1 (en) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
AU2012339870B2 (en) 2011-11-15 2017-06-29 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3066969A1 (en) * 2017-06-28 2019-01-03 Glaxosmithkline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2020033919A1 (en) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
AU5177390A (en) * 1989-03-10 1990-10-09 Idemitsu Kosan Company Limited Pyridine derivatives and their salts, and insecticidal/acaricidal agent containing the same as active ingredient
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4222565A1 (de) * 1992-07-09 1994-01-13 Hoechst Ag Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE4311967A1 (de) * 1993-04-10 1994-10-13 Hoechst Ag Smektische Flüssigkristallmischung
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705346B1 (fr) * 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE19544100A1 (de) * 1995-11-27 1997-05-28 Hoechst Schering Agrevo Gmbh Cyclohexylmethyl- und Cyclohexylidenmethyl-Pyridine, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US6518423B1 (en) * 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
US5965570A (en) * 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
WO2000046203A2 (en) * 1999-02-04 2000-08-10 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
AR025884A1 (es) * 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
AU2001292255A1 (en) * 2000-11-21 2002-06-03 Mitsubishi Chemical Corporation Process for producing 2-(4-pyridyl)ethanethiol
CA2443108A1 (en) * 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療又は予防用nr2b受容体拮抗薬
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
MXPA04011470A (es) * 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
KR101078098B1 (ko) * 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
CA2515963A1 (en) * 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
CN1898235A (zh) * 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
HRP20090093T3 (en) * 2004-06-04 2009-03-31 Arena Pharmaceuticals Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP2308840A1 (en) * 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
AR064735A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto

Similar Documents

Publication Publication Date Title
JP2008525416A5 (enExample)
JP2011527334A5 (enExample)
JP2008525417A5 (enExample)
JP2011527335A5 (enExample)
JP2009535358A5 (enExample)
JP2009532453A5 (enExample)
JP2013523897A5 (enExample)
JP2009519243A5 (enExample)
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
JP2012505871A5 (enExample)
JP2007534702A5 (enExample)
JP2009534468A5 (enExample)
JP2009530424A5 (enExample)
JP2010514832A5 (enExample)
JP2011527332A5 (enExample)
JP2010524932A5 (enExample)
JP2010514831A5 (enExample)
JP2007508359A5 (enExample)
JP2010511626A5 (enExample)
JP2011519910A5 (enExample)
JP2010511721A5 (enExample)
JP2008546770A5 (enExample)
JP2008526724A5 (enExample)
JP2007517044A5 (enExample)
JP2008538381A5 (enExample)